Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

@article{Moyer2012ScreeningFP,
  title={Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement},
  author={Virginia A. Moyer},
  journal={Annals of Internal Medicine},
  year={2012},
  volume={157},
  pages={120 - 134}
}
  • V. Moyer
  • Published 17 July 2012
  • Medicine
  • Annals of Internal Medicine
DESCRIPTION Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for prostate cancer. METHODS The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer. RECOMMENDATION The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation).This recommendation applies to men… 
View on PubMed
annals.org
1,657 Citations
Highly Influential Citations
23
Background Citations
187
Methods Citations
45
Results Citations
9

Topics from this paper

    1,657 Citations

    Citation Type

    Citation Type

    Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
    TLDR
    The USPSTF concludes with moderate certainty that the net benefit of PSA-based screening for prostate cancer in men aged 55 to 69 years is small for some men.
    Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.
    Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations Prostate-specific antigen (PSA) screening is a widely debated practice in the United States, given…
    The politics of prostate cancer screening.
    Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
    Long‐term consequences of the USPSTF Grade D recommendation for prostate‐specific antigen screening
    TLDR
    By summarily rejecting any benefits of PSA screening in favor of highlighting treatment toxicities, the USPSTF ignored the extensive work being done to mitigate these toxicities and sent shockwaves through the urologic oncology community.
    New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough
    TLDR
    Since the 1990s, when the use of Prostate-Specific Antigen (PSA) began in clinical practice, the mortality rate from PC has decreased by around 50%, and policies, early diagnosis and treatment are pointed out as responsible for this reduction.
    Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
    Recently, the US Preventive Services Task Force (USPSTF) published a review of the evidence for screening for prostate cancer1 and made a clear recommendation against screening. By giving a grade of…
    Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
    Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
    TLDR
    Prostate-specific antigen-based screening results in small or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary.
    Prostate Cancer Screening and the Associated Controversy.
    ...
    1
    2
    3
    4
    5
    ...

    References

    SHOWING 1-10 OF 123 REFERENCES
    Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
    • Medicine
      Annals of internal medicine
    • 2008
    TLDR
    Current evidence is insufficient to assess the balance of benefits and harms of screening for prostate cancer in men younger than age 75 years (I statement) and do not screen for prostatecancer in men age75 years or older (Grade D recommendation).
    Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
    TLDR
    Prostate-specific antigen-based screening results in small or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessary.
    Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
    Prostate cancer is the most common nonskin cancer in U.S. men. An estimated 218890 men received a new diagnosis of prostate cancer in 2007, and 1 in 6 men will receive a diagnosis in their lifetime…
    Early detection of prostate cancer: AUA Guideline.
    Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians
    TLDR
    The American College of Physicians developed this guidance statement for clinicians by assessing current prostate cancer screening guidelines developed by other organizations to critically review available guidelines to help guide internists and other clinicians in making decisions about screening for prostate cancer.
    Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
    TLDR
    A systematic review of the evidence on screening for prostate cancer found no direct evidence connecting screening and reduced mortality, and searched for indirect evidence on the yield of screening, the efficacy and harms of various forms of treatment for early prostate cancer, and the costs and cost-effectiveness.
    Prostate specific antigen best practice statement: 2009 update.
    An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
    TLDR
    No evidence is found to support the recommendation that men with high PSA velocity should be biopsied in the absence of other indications; this measure should not be included in practice guidelines.
    Mortality results from a randomized prostate-cancer screening trial.
    TLDR
    After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.
    ...
    1
    2
    3
    4
    5
    ...